CHIR-258 |
GFKI-258 |
NVP-TKI258 |
TKI-258 |
DOVITINIB |
CHIR 258 |
4-AMINO-5-FLUORO-3-[5-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]QUINOLIN-2(1H)-ONE |
TKI258 |
TKI 258 |
chemidplus:405169-16-6 |
chembl:CHEMBL522892 |
drugbank:05928 |
Drug Class | Kinase Inhibitors |
FDA Approval | not approved |
Drug Class | Small molecule |
Drug Indications | antineoplastic agent |
Pharmaceutical Developer | Novartis |
Source Reported Drug Name(s) | Dovitinib/TKI258 |
Drug Class | FGFR Inhibitor |
inhibitor (inhibitory) |
Novel drug target | Established target |
Trial Name | dovitinib, TKI-258, CHIR-258 |
Variant Effect | gain-of-function |
inhibitor (inhibitory) |
Notes | |
Indication/Tumor Type | bladder urothelial carcinoma |
Approval Status | Preclinical - Cell culture |
n/a |
inhibitor (inhibitory) |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | sensitive |
Approval Status | Preclinical |
n/a |
inhibitor (inhibitory) |
n/a |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | sensitive |
Approval Status | Phase I |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
Reported Cancer Type | Prostate |
inhibitor (inhibitory) |
Trial Name | dovitinib, TKI-258, CHIR-258 |
Novel drug target | Established target |
Mechanism of Interaction | Platelet-derived growth factor receptor inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | Stem cell growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
Trial Name | dovitinib, TKI-258, CHIR-258 |
inhibitor (inhibitory) |
Mechanism of Interaction | Platelet-derived growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
Notes |
n/a |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase receptor FLT3 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
TKI258 | Development Name |
CHIR-258 | Development Name |
DOVITINIB | Generic Name |
Drug Class | Kinase Inhibitors |
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one | PubChem Drug Name |
9886808 | PubChem Drug ID |
Dovitinib | Drug Trade Name |
Drug Class | FGFR Inhibitor |
Source Reported Drug Name(s) | Dovitinib/TKI258 |
Pharmaceutical Developer | Novartis |
Drug Indications | antineoplastic agent |
Drug Class | Small molecule |
FDA Approval | not approved |
CHEMBL522892 | ChEMBL Drug ID |
DOVITINIB | Primary Drug Name |
DOVITINIB | Drug Generic Name |
TKI-258 | Drug Synonym |
D07OZR | TTD Drug ID |